Background: Hematopoietic stem cell transplantation (HSCT) is a medically complicated therapy with a long recovery time. In Tunisia, the National Health Insurance Fund (CNAM) covers only the first year post-transplantation, after which the costs are borne by the hospital. Objective: Describe complications that can occur during the second year post-allogeneic HSCT and calculate direct costs in different groups of patients. Methods: In this pharmacoeconomic study, medical records of the second year post-allogeneic HSCT were collected. Studied variables included frequent observed complications and medical and non-medical direct costs. Results: The average total direct cost in the population during the second year post-transplantation was $11,571, 97% of which represents direct medical costs Drugs accounted for the largest share (80%) of total direct costs, dominated by the cost of antifungals (52%) and antivirals (26%) drug . Cytomegalovirus status was seen in 9.3% of patients and was associated with a seven-fold increase in direct costs (p < 0.001).In patients who developed chronic GVHD, the average direct cost was three times higher than for those who did not (p = 0.032). Conclusion: Given the importance of direct costs in the post-transplantation period a review of the hospital financing mechanism and a new convention with the CNAM is crucial..
Introduction: New procedures and diagnostic tests in hematopoietic stem cell transplantation (HSCT) are associated with a significant increase in costs. The last cost estimate of allogeneic HSCT done in Tunisia was in 1996 and concerned only direct medical costs. Therefore, an updated cost analysis is needed.
Our objective is to describe the experience and challenges of using Managed Entry Agreements (MEAs) in Algeria, Morocco, and Tunisia. We conducted online interviews with key decision-makers in Algeria, Morocco, and Tunisia between March 2021 and December 2023. The questionnaire captured experience with MEAs, types of agreements implemented, and challenges to implementing MEAs. Three, five, and seven participants working, respectively, in the Algerian, Moroccan, and Tunisian pharmaceutical sectors, participated in the interviews. Participants were from the public (8/15) and the private sector (7/15). Only Tunisian respondents reported having dealt with MEAs contracts, such as financial-based agreements (FBAs) related to standard discounts and volume-based price discounts. All respondents were aware of the potential need for structuring contracts differently for expensive medicines. Hurdles in implementing MEAs noted by respondents were mainly related to the absence of a legal framework and the lack of budget allocated for new medicines. Most respondents projected an increase in the use of MEAs to improve reimbursement and access to new, highly priced medicines. Recommendations include strengthening pricing, reimbursement processes, and HTA use. The adoption of FBAs is suggested as a practical initial approach.
1 September 2025 in ClinicoEconomics and Outcomes Research
Purpose: Evaluate the costs related to the pediatric haplo-SCT and adult and pediatric geno-SCT at the CNGMO in order to establish a tailored reimbursement package by the Tunisian Health Insurance Fund. Patients and Methods: This pharmaco-economic study compared the cost of pediatric haplo-SCT to adult and pediatric geno identical hematopoietic stem cell transplantation (geno-SCT) using the activity-based costing method. The cost assessment was conducted from the hospital’s perspective and considered direct medical and non-medical costs. Results: The cost assessment indicated that pediatric patients incurred higher expenses than adult patients. Furthermore, haplo-SCT was more expensive than geno-SCT for pediatric patients. The conditioning regimens used before haplo-SCT are more intensive than other preparative regimens and typically require longer inpatient therefore resulting in more costs. Complications, such as infections during the early phase of neutropenia and late-onset issues following hematopoietic stem cell transplantation (HSCT), particularly graft-versus-host disease (GVHD) and cytomegalovirus (CMV) reactivation, significantly contribute to increased procedural costs. Conclusion: This study sets the standards for new specific packages for haplo-SCT and geno-SCT in pediatric patients.
12 October 2026 in Journal of Oncology Pharmacy Practice
Introduction: Ensuring the safety and quality of cytotoxic drug preparation is a core component of oncology pharmacy practice. In emerging settings, structured audit tools are essential to assess practices and support continuous quality improvement. Objective: To develop a standardized audit tool for assessing compliance with current standards for hospital cytotoxic drug preparation and to apply it in a specialized oncology hospital. Methods: A working group developed a structured audit tool based on 2023 Good Preparation Practices and international recommendations. The tool included domains, subdomains, and explicit compliance criteria. A 15-day audit was conducted using direct observation, document review, and staff interviews. Deviations were classified by criticality. Data were analyzed quantitatively using a standardized Excel-based framework. Results: A total of 913 criteria were included in the audit tool, of which 289 were deemed not applicable at the hospital level. Consequently, 624 criteria were assessed across seven thematic areas. The overall compliance rate was 70%. Among the evaluated criteria, 23% were non-compliant and 7% were partially compliant. Among the non-compliant criteria, 27.4% were associated with a potential risk of adverse events. The proposed improvement actions were categorized into short-term and long-term measures. Conclusions: This study provides a structured audit framework for evaluating compliance with current Good Preparation Practices in hospital cytotoxic drug preparation. Its application highlighted priority areas for improving the quality and safety of preparation practices.